News Articles

Update on the timeline for Vifor Pharma tender offer ST. GALLEN, Switzerland -Thursday 12 May 2022

(BUSINESS WIRE) -- Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. While some antitrust...

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis... -Thursday 28 April 2022  

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022 (BUSINESS WIRE)-- Regulatory News: This press release features...

DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy -Monday 4 April 2022

Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended RAASi therapy Veltassa® prevented the recurrence of hyperkalemia events, potentially leading to better patient...

Publication of definitive end result for Vifor Pharma tender offer -Monday 28 March 2022  

(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the end result of its public tender...

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful -Tuesday 8 March 2022  

(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the Interim Result of its public tender...

Vifor Pharma reports sustained growth in 2021 -Thursday 17 February 2022

(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject® / Injectafer® sales from the second quarter 2021 on, and sustained by...

Vifor Pharma appoints two new members to the Executive Committee -Wednesday 2 February 2022

Executive appointments to strengthen financial and legal leadership during the transformation of the company (BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros...

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis -Wednesday 19 January 2022  

First orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 (BUSINESS WIRE)-- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European...

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd. -Tuesday 18 January 2022  

(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all...

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa® -Tuesday 21 December 2021

Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer) in high risk patient population with heart failure Results suggest that treatment with Veltassa® is beneficial in heart failure...

Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation -Monday 20 December 2021  

(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group...

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma -Thursday 16 December 2021  

Focus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product facilities to CordenPharma, reducing organizational complexity, and optimizing cost structure CordenPharma to assume...

CSL Limited announces tender offer to acquire Vifor Pharma Ltd -Tuesday 14 December 2021

Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1 Proposed ordinary dividend expected to be declared at AGM of 26 April 2022 of CHF 2 to...

Vifor Pharma comments on media speculation -Monday 13 December 2021

(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions. About Vifor Pharma...

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease -Saturday 11 December 2021

Vamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease (SCD) SCD is a rare blood disorder with currently limited treatment options Topline results are...

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee -Friday 10 December 2021

  Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022 Responsibilities of Sales, Marketing and Market Access to be streamlined under Chief Commercial Officer role to prioritize commercial execution (BUSINESS WIRE)-- Regulatory News: AD HOC...

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute... -Friday 10 December 2021  

(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from...

Vifor Pharma comments on market speculations -Friday 3 December 2021

(BUSINESS WIRE) -- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate the growth of the...

Vifor Pharma announces changes to the Executive Committee as CFO retires -Tuesday 30 November 2021

(BUSINESS WIRE)-- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021 at his own request. Vifor Pharma is currently in the recruiting process for the...

Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis -Friday 26 November 2021

Iron Deficiency Day unites a strong international coalition dedicated to raising international awareness on the serious health impact of iron deficiency and iron deficiency anemia1 Patient access to diagnosis and treatment of iron deficiency directly affected by COVID-19 pandemic This...